Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeWages, Salaries and Other
Others
Ratios

Sagimet Biosciences (SGMT) EBITDA (2023 - 2024)

Sagimet Biosciences (SGMT) has 2 years of EBITDA data on record, last reported at -$16.4 million in Q4 2024.

  • For Q4 2024, EBITDA fell 102.09% year-over-year to -$16.4 million; the TTM value through Dec 2024 reached -$45.4 million, down 63.41%, while the annual FY2025 figure was -$51.1 million, 12.74% down from the prior year.
  • EBITDA reached -$16.4 million in Q4 2024 per SGMT's latest filing, down from -$14.2 million in the prior quarter.
  • Across five years, EBITDA topped out at -$6.4 million in Q3 2023 and bottomed at -$16.4 million in Q4 2024.